Vesugen

1. Overview

Vesugen is a synthetic tripeptide with the amino acid sequence Lys-Glu-Asp (KED) and a molecular weight of 390.39 g/mol (C15H26N4O8). It was developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology as a vascular-specific bioregulator -- a short-chain peptide proposed to restore endothelial function through direct interaction with gene regulatory elements in vascular tissue [7] [8].

Vesugen was identified through amino acid analysis of vascular wall protein extracts, following the same methodology Khavinson used to derive Epithalon from pineal tissue and Vilon from thymic tissue [10]. The tripeptide does not adopt higher-order secondary or tertiary structures under standard laboratory conditions, existing as a linear peptide chain at physiological pH [16].

Within Khavinson's peptide bioregulator classification, Vesugen belongs to the "cytogen" class of fully synthetic defined peptides, as distinguished from the "cytomax" class of natural organ extracts [8] [9]. It has not achieved pharmaceutical registration in any country and is marketed as a peptide dietary supplement. Clinical data, while limited, includes studies in elderly patients with coronary heart disease, atherosclerosis, and peripheral arterial insufficiency. The most rigorous preclinical data comes from Alzheimer's disease mouse model studies examining neuroprotective effects [1].

The KED sequence is notably shared by the first three residues of both Testagen (KEDG, testicular bioregulator) and Livagen (KEDA, hepatic bioregulator), raising questions about the specificity of tissue-targeting claims within the Khavinson peptide family [5].

Sequence

Lys-Glu-Asp (KED)

Molecular Weight

390.39 g/mol

Chemical Formula

C15H26N4O8

Mechanism

Epigenetic regulation of endothelin-1, connexin GJA1/Cx43, and SIRT1 in vascular endothelium; neuroprotective gene modulation

Routes Studied

Oral (capsule), intraperitoneal (animal studies)

Regulatory Status

Not approved as a pharmaceutical; marketed in Russia as a peptide dietary supplement

Developer

V.Kh. Khavinson, St. Petersburg Institute of Bioregulation and Gerontology

2. Mechanism of Action

Vesugen is proposed to act through epigenetic modulation of gene expression in vascular endothelial cells and neural tissue, with several specific molecular pathways identified in preclinical research.

Endothelin-1 Regulation

In vitro studies using normal, atherosclerotic, and restenotic vascular endothelium demonstrated that KED normalized the expression of endothelin-1 (EDN1), a potent vasoconstrictor peptide that is characteristically elevated in atherosclerotic and restenotic conditions [2]. Endothelin-1 overexpression promotes vasoconstriction, vascular smooth muscle proliferation, and inflammation; its normalization by KED suggests a potential anti-atherosclerotic mechanism. Molecular docking studies proposed that KED interacts with specific DNA sequences in the EDN1 promoter region [5].

Connexin and Endothelial Communication

KED modulates expression of connexin proteins, particularly GJA1 (connexin 43, Cx43), which form gap junctions essential for cell-to-cell communication in the endothelial layer [2]. Enhanced connexin expression is associated with improved endothelial barrier integrity, coordinated vasomotor responses, and efficient nutrient/waste exchange across the vessel wall. Loss of connexin function with aging contributes to endothelial dysfunction and impaired vascular homeostasis.

SIRT1 Pathway

Preclinical research has associated Vesugen with activation of sirtuin 1 (SIRT1), a NAD-dependent deacetylase that plays central roles in cellular stress resistance, metabolic regulation, and longevity signaling [10]. SIRT1 activation in endothelial cells promotes nitric oxide (NO) production through deacetylation and activation of endothelial nitric oxide synthase (eNOS), supporting vasodilation and anti-inflammatory endothelial phenotypes. KED may indirectly support mitochondrial function and energy-sensing pathways (PGC-1-alpha signaling) through SIRT1-mediated effects.

Nitric Oxide Enhancement

In aged Wistar rats, Vesugen treatment was associated with improved endothelial cell morphology and increased nitric oxide production, suggesting enhanced vasodilation capacity and improved microcirculation [10]. NO is the primary mediator of endothelium-dependent vasodilation, and its declining bioavailability with age is a hallmark of endothelial dysfunction.

Proliferative Restoration in Aged Endothelium

Studies in dissociated vascular endothelial cell cultures from young and old animals demonstrated that KED stimulated expression of Ki-67, a proliferation-associated protein that decreases during aging [2]. This suggests that KED may counteract age-related decline in endothelial regenerative capacity.

Neuroprotective and Neurogenic Effects

In the 5xFAD transgenic Alzheimer's disease mouse model, daily intraperitoneal KED administration prevented dendritic spine loss and modulated expression of genes implicated in AD pathogenesis [1]. Molecular docking studies identified KED binding sites in promoter regions of CASP3 (apoptosis), NES and GAP43 (neuronal differentiation), APOE (lipid metabolism/AD risk), SOD2 (antioxidant defense), PPARA and PPARG (metabolic regulation), and GDX1 genes [1] [4]. KED also regulated expression of cell aging genes p16 and p21 and promoted neuronal differentiation markers including nestin and GAP43 protein [4] [17].

Epigenetic Framework

Like other Khavinson peptides, Vesugen's mechanism is proposed to involve direct interaction with DNA and histone proteins [5] [6]. The peptide is proposed to bind to specific hexanucleotide sequences and modulate chromatin structure, shifting the balance from transcriptionally inactive heterochromatin toward active euchromatin in vascular and neural cells [5] [14]. This mechanism remains theoretically supported by molecular modeling but has not been confirmed through direct structural biology experiments.

3. Researched Applications

Coronary Heart Disease and Atherosclerosis

In a clinical study, 53 patients with ischaemic heart disease and atherosclerosis (age 50-82 years) received oral Vesugen at 0.2 mg twice daily for one month [9]. The active treatment group demonstrated:

• Fewer episodes of angina pectoris
• Reduced cardiac arrhythmias
• Improved sleep quality
• In hypertensive subgroup: long-term remission between hypertensive crises
• Decreased total cholesterol and VLDL content in blood

These results were reported by Khavinson's group and have not been replicated in independent, Western clinical trials.

Peripheral Arterial Insufficiency

A study in elderly patients (age 50-82 years) with chronic arterial insufficiency of the lower limbs evaluated peptide bioregulator treatment including Vesugen [3]. The treatment improved clinical parameters of peripheral arterial disease in the elderly population. This study focused on complex bioregulator therapy rather than Vesugen monotherapy.

Alzheimer's Disease (Preclinical)

The most methodologically rigorous Vesugen data comes from the 5xFAD Alzheimer's disease mouse model study [1]. Daily intraperitoneal KED at 0.1 mcg/mouse from age 2-4 months demonstrated:

• Prevention of dendritic spine loss characteristic of AD progression
• Trend toward increased neuroplasticity
• Regulation of neuronal differentiation markers (nestin, GAP43)
• Modulation of AD-associated genes (APOE, SUMO, IGF1)

While encouraging, these findings have not progressed to human clinical trials for Alzheimer's disease.

Essential Hypertension

In elderly patients with essential hypertension, peroral Vesugen administered in combination with standard hypotensive therapy led to longer remission periods between hypertensive crises and improved lipid profiles compared to standard therapy alone [9].

4. Clinical Evidence

The clinical evidence for Vesugen is limited:

Clinical Studies: Small clinical studies in elderly patients with coronary heart disease, atherosclerosis, and peripheral arterial insufficiency have reported improvements in cardiovascular parameters [3] [9]. These studies were not double-blind or placebo-controlled and originated from Khavinson-affiliated institutions.

Animal Studies: The 5xFAD Alzheimer's disease mouse model study [1] and aged Wistar rat studies provide the strongest preclinical evidence for vascular and neuroprotective effects.

In Vitro Studies: Cell culture work on vascular endothelium demonstrates modulation of endothelin-1, connexin expression, and Ki-67 proliferative markers [2].

Molecular Studies: Docking simulations and gene expression analyses identify specific DNA binding targets and downstream gene regulatory effects [4] [5] [17].

No multicenter, randomized, placebo-controlled trials have been published. No clinical trials are registered on ClinicalTrials.gov.

5. Dosing in Published Research

The following doses have been reported in published research. These are not recommendations and should not be interpreted as therapeutic guidance.

The oral dose used in the coronary heart disease study (0.2 mg twice daily) represents the most relevant human dosing data [9]. Animal studies used microgram-range intraperitoneal doses. No formal dose-finding, dose-response, or pharmacokinetic studies have been published for Vesugen in humans.

6. Safety and Side Effects

No adverse events have been reported in published Vesugen studies [1] [3] [9]. In the coronary heart disease study, oral Vesugen at 0.2 mg twice daily for one month was well-tolerated in elderly patients [9].

However, substantial safety data gaps exist:

• No formal toxicology studies meeting regulatory standards have been published.
• No drug interaction studies have been conducted, despite the target population (elderly cardiovascular patients) typically taking multiple medications.
• No pharmacokinetic data are available for oral formulations.
• Long-term safety data from controlled studies are absent.
• Theoretical concerns regarding chronic modulation of endothelin-1 and connexin expression have not been systematically evaluated.
• The interaction between Vesugen and standard cardiovascular medications (statins, ACE inhibitors, beta-blockers, anticoagulants) is unknown.

7. Sequence Relationships

Vesugen (KED) occupies a central position in the Khavinson peptide family tree:

• KED (Vesugen) -- vascular bioregulator (tripeptide)
• KEDG (Testagen) -- testicular bioregulator (KED + Gly)
• KEDA (Livagen) -- hepatic bioregulator (KED + Ala)
• KE (Vilon) -- thymic bioregulator (first two residues of KED)

The KED sequence is thus a common structural motif shared across multiple organ-targeted bioregulators. Whether the addition of a single C-terminal amino acid (Gly for testes, Ala for liver, none for vessels) can redirect tissue specificity through DNA-binding selectivity remains a central and unresolved question in Khavinson's bioregulator framework [5] [16].

8. Limitations and Transparency

• All clinical studies originate from Khavinson-affiliated Russian institutions with no independent replication.
• Clinical studies were small, non-randomized, and not placebo-controlled.
• Vesugen is not registered as a pharmaceutical in any country.
• The dual vascular-neuroprotective activity described for KED challenges the concept of strict organ specificity central to bioregulator theory.
• Molecular docking simulations supporting DNA-binding mechanisms have not been validated by crystallographic or biophysical binding studies.
• The relationship between KED sequence and closely related Khavinson peptides (KEDG, KEDA, KE) raises unresolved questions about the mechanistic basis of claimed tissue specificity.

9. Related Peptides

See also: Testagen, Vilon, Epithalon, Thymalin

10. References

1. [1] Khavinson VK, Linkova NS, Diatlova AS, Trofimova SV (2021). Neuroprotective effects of tripeptides -- epigenetic regulators in mouse model of Alzheimer's disease. Pharmaceuticals. DOI PubMed
2. [2] Khavinson VK, Linkova NS, Tarnovskaya SI (2014). Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging. Adv Gerontol. PubMed
3. [3] Khavinson VK et al. (2014). The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people. Adv Gerontol. PubMed
4. [4] Khavinson VK, Linkova NS (2021). Peptide KED: molecular-genetic aspects of neurogenesis regulation in Alzheimer's disease. Bull Exp Biol Med. DOI
5. [5] Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR (2021). Peptide regulation of gene expression: a systematic review. Molecules. DOI PubMed
6. [6] Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). DOI PubMed
7. [7] Khavinson VK (2002). Peptides and ageing. Neuro Endocrinol Lett. PubMed
8. [8] Khavinson VK (2020). Peptide medicines: past, present, future. Klin Med (Mosk). PubMed
9. [9] Khavinson VK, Kuznik BI, Ryzhak GA (2013). Peptide bioregulators: a new class of geroprotectors. Report 2. Clinical studies results. Adv Gerontol. PubMed
10. [10] Anisimov VN, Khavinson VK (2010). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
11. [11] Khavinson VK, Morozov VG (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. PubMed
12. [12] Khavinson VK, Linkova NS, Kvetnoy IM (2020). Peptides: prospects for use in the treatment of COVID-19. Molecules. DOI PubMed
13. [13] Kuznik BI, Linkova NS, Khavinson VK (2022). Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. Int J Mol Sci. DOI PubMed
14. [14] Khavinson VK, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A (2014). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. DOI PubMed
15. [15] Khavinson VK, Linkova NS, Dyatlova AS, Kuznik BI, Umnov RS (2021). The use of Thymalin for immunocorrection and molecular aspects of biological activity. Biol Bull Rev. DOI PubMed
16. [16] Ilina A, Khavinson V, Linkova N, Petukhov M (2025). Overview of Epitalon -- Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. DOI PubMed
17. [17] Matveeva VG et al. (2022). Neuroepigenetic mechanisms of action of ultrashort peptides in Alzheimer's disease. Int J Mol Sci. PubMed